Molinalogo

Measure

2022

2023

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

NA

69.05%

64.90%

Annual Dental Visits (ADV)

NB

NB

54.60%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

22.22%

52.09%

46.74%

Appropriate Testing for Pharyngitis (CWP)

69.54%

74.26%

77.56%

Appropriate Treatment for Upper Respiratory Infection (URI)

93.49%

94.06%

93.08%

Asthma Medication Ratio (AMR) Total

59.53%

63.59%

69.41%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

59.02%

77.33%

66.19%

Blood Pressure Control (<140/90) for Patients With Diabetes (BPD)

59.37%

54.99%

68.61%

Breast Cancer Screening (BCS)

35.66%

34.58%

55.25%

Cervical Cancer Screening (CCS)

37.23%

44.04%

59.85%

Childhood Immunization Status (CIS) Combination #10

30.66%

22.63%

35.04%

Chlamydia Screening in Women (CHL) Total

38.81%

37.39%

61.07%

Controlling High Blood Pressure (CBP)

44.77%

40.88%

65.45%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

84.62%

78.22%

80.86%

Eye Exam for Patients With Diabetes (EED)

44.77%

46.72%

56.20%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

16.29%

NB

27.73%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

20.12%

NB

46.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

28.52%

NB

41.03%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

25.30%

NB

37.31%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

12.50%

NB

57.90%

Hemoglobin A1c Control for Patients With Diabetes (HBD) HbA1c Control (<8%)

38.20%

44.04%

55.72%

Immunizations for Adolescents (IMA) Combination #2

26.28%

23.11%

38.93%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

NB

NB

16.94%

Kidney Health Evaluation for Patients with Diabetes (KED)

30.96%

31.80%

38.80%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Blood Glucose and Cholesterol Testing Total

NA

21.73%

39.01%

Pharmacotherapy for Opioid Use Disorder (POD) Total

14.02%

13.51%

31.93%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

56.79%

60.71%

75.79%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

75.31%

76.79%

86.96%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

102.23%

66.38%

≤ 92.72%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

63.50%

76.40%

86.86%

Prenatal and Postpartum Care (PPC) Postpartum Care

65.94%

72.02%

80.78%

Prenatal Immunization Status (PRS) Combination Rate

18.10%

16.53%

25.81

Risk of Continued Opioid Use (COU) 31-Day Total

5.74%

3.97%

≤ 2.45%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

67.61%

70.59%

81.64%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

58.33%

60.42%

73.63%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

59.67%

54.98%

67.07%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

59.50%

62.99%

70.37%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

NA

NB

63.89%

Use of Imaging Studies for Low Back Pain (LBP)

73.96%

74.19%

75.44%

Use of Opioids at High Dosage (HDO)

7.50%

3.05%

≤ 2.19%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

1.61%

0.79%

≤ 0.87%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

57.42%

54.99%

83.21%